Development and Validation of a Novel Eye-Tracking Software-based Platform to Extract Oculometric Measures
Launched by NEURALIGHT · Jul 25, 2022
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new software platform called NeuraLight that uses eye-tracking technology to measure eye movements. Researchers want to see how well this system can collect data from healthy individuals and compare its results to a well-established eye-tracking system. The goal is to ensure that the NeuraLight system is effective and accurate in capturing important information about how our eyes move.
If you’re between 18 and 90 years old, have normal or corrected vision, and can follow instructions, you might be eligible to participate. However, you cannot have certain conditions, like a history of epilepsy or other neurological diseases. Participants will be asked to sit calmly for about 20 minutes while the eye-tracking technology is used. This study is currently recruiting individuals, so if you or someone you know is interested in helping to improve eye movement research, this could be a great opportunity!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women ages between 18 and 90 years old
- • Normal or corrected vision
- • Ability to follow instructions
- • Willing and able to sign an informed consent form
- Exclusion Criteria:
- • Inability to sit for 20 minutes on a chair in a calm manner
- • Personal or 1st degree relative history of epilepsy
- • Additional neurological diseases
- • Drug or alcohol abuse
About Neuralight
Neuralight is a pioneering clinical trial sponsor focused on advancing innovative therapeutic solutions for neurological disorders. With a commitment to enhancing patient outcomes through cutting-edge research and development, Neuralight leverages state-of-the-art technology and a multidisciplinary approach to drive clinical trials that prioritize safety, efficacy, and patient-centric care. The organization collaborates with leading researchers, healthcare professionals, and regulatory bodies to ensure the highest standards of scientific rigor and ethical practices in its clinical investigations. Through its dedication to transforming the landscape of neurology, Neuralight aims to deliver breakthrough treatments that improve the quality of life for individuals affected by complex neurological conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wilmington, Delaware, United States
Patients applied
Trial Officials
Eitan Raveh, PhD
Principal Investigator
NeuraLight
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials